Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant

  title={Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant},
  author={Stephanie L. Born and David V. Gauvin and Suman K Mukherjee and Richard J. Briscoe},
  journal={Regulatory Toxicology and Pharmacology},

Figures and Tables from this paper

Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant.

Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.

In this large, valid human abuse potential study, daridorexant showed dose-related drug-liking among recreational sedative drug users with lower effects at the highest phase-3 dose, and similar effects at higher doses compared to supratherapeutic doses of suvoreXant and zolpidem.

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

For all doses, LEM demonstrated abuse potential versus PBO and appeared to have a similar abuse potential profile to ZOL and SUV in this study population.

Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?

Several clinical trials are currently underway to examine the efficacy of suvorexant in normalizing sleep outcomes, as well as craving, stress, and sleep indices, in OUD and other substance use disorder patients, and these studies represent an important step toward repurposing suvORExant for addiction.

Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.

It is shown that acute and chronic suvorexant promotes both rapid eye movement (REM) and non-REM (NREM) sleep without inducing cataplexy in mice, and orexin synthesis is inhibited resulting in susceptibility to narcolepsy-like symptoms in mice under certain conditions.

Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

The involvement of glutamatergic, endocannabinoid and orexin signaling systems in the development, maintenance and expression of addiction-like behaviours in animal models of opioid addiction, and as potential and novel targets to expand therapeutic options to treat OUD are explored.

Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders

Recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction are discussed and potential challenges and opportunities for the application of oxin receptor antagonists to clinical interventions are discussed.

Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis

The results suggest that the orexin system may be a novel pharmacological target for the treatment of comorbid psychosis related to PTSD.



Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

The overall incidence of abuse-related adverse events, such as euphoric mood and hallucination, was numerically lower with suvorexant than zolpidem, suggesting that the overall abuse liability of suvorxant may be lower than zOLpidem.

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats, dogs, and rhesus monkeys, highlighting a unique opportunity to develop dual orexin antagonists as a novel therapy for insomnia.

In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans

Suvorexant is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia and its absorption, disposition and potential for CYP-mediated drug interactions in humans is described.

The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat.

The findings suggest that almorexant itself does not exert conditioned rewarding effects in the rat and that it may acutely interfere with the expression of CPP or locomotor sensitization in a drug-dependent manner (monoaminergic psychostimulants vs. opiates).

Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

Combined genetic and pharmacological approaches indicate that orexin signaling may represent a confluence of sleep, feeding, and reward pathways and selective oX2 receptor antagonism takes advantage of these properties toward the development of novel insomnia therapeutics.

Abuse liability assessment of hydrocodone under current draft regulatory guidelines.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

In healthy young men without sleep disorders, suvorexant promoted sleep with some evidence of residual effects at the highest doses, and was well tolerated.